These concerns are based on the concept that angiotensin‐converting enzyme 2 (ACE2), an enzyme potentially upregulated by ACEIs/ARBs use, is the viral entry receptor that COVID‐19 uses to enter lung cell,2 coupled with the observation of high prevalence of hypertension and other cardiovascular comorbidities among COVID‐19 patients who have poor outcomes.3 This evidence concerns the gene ACE2 and COVID-19.